Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA at a ratio of about 5:2. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA at a ratio of about 5:2. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA at a ratio of about 5:2. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA at a ratio of about 5:2. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: Disclosed herein are methods for improving user acceptance of an oral dosage form containing an active ingredient for use as a supplement and/or medicament by masking undesirous flavors, odors, tastes, smells, and/or palatability associated with certain active ingredients. A user may be a human and/or animal in need of a particular active ingredient. A preferred embodiment of the methods of the present invention may include: (1) selecting the oral dosage form; (2) incorporating an active ingredient into the oral dosage form; and (3) applying at least one substance to improve user acceptance of the oral dosage form. A substance to improve user acceptance of the oral dosage form may include a fragrance, flavorant, and/or appearance modification agent.

Abstract: Disclosed herein are compositions containing synergistic combinations of marine mollusk tissue and at least one fatty acid configured into a delivery formulation suitable for administration to humans and animals. A preferred embodiment of the compositions of the present invention may utilize an extract of green-lipped mussel and at least one polyunsaturated fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), eicosatetraenoic acid (ETA), docosapentaenoic acid (DPA), and combinations thereof, and a delivery formulation selected from tablets, capsules, liquids, oils, suspensions, emulsions, solutions, and powders. Also disclosed herein are methods for ameliorating and/or mitigating inflammatory-mediated conditions.